Sökning: WFRF:(Banerjee Joanna) > Posterior reversibl...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05015naa a2200565 4500 | |
001 | oai:DiVA.org:uu-381105 | |
003 | SwePub | |
008 | 190405s2019 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:140589202 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3811052 URI |
024 | 7 | a https://doi.org/10.1002/pbc.275942 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1405892022 URI |
040 | a (SwePub)uud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Anastasopoulou, Stavroulau Karolinska Institutet4 aut |
245 | 1 0 | a Posterior reversible encephalopathy syndrome in children with acute lymphoblastic leukemia :b Clinical characteristics, risk factors, course, and outcome of disease |
264 | c 2018-12-27 | |
264 | 1 | b WILEY,c 2019 |
338 | a print2 rdacarrier | |
520 | a Background: Posterior reversible encephalopathy syndrome (PRES) is a distinct entity with incompletely known predisposing factors. The aim of this study is to describe the incidence, risk factors, clinical course, and outcome of PRES in childhood acute lymphoblastic leukemia (ALL).Procedure: Patients aged 1.0 to 17.9 years diagnosed with ALL from July 2008 to December 2015 and treated according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 protocol were included. Patients with PRES were identified in the prospective NOPHO leukemia toxicity registry, and clinical data were collected from the medical records.Results: The study group included 1378 patients, of whom 52 met the criteria for PRES. The cumulative incidence of PRES at one month was 1.7% (95% CI, 1.1-2.5) and at one year 3.7% (95% CI, 2.9-4.9). Older age (hazard ratios [HR] for each one-year increase in age 1.1; 95% CI, 1.0-1.2, P = 0.001) and T-cell immunophenotype (HR, 2.9; 95% CI, 1.6-5.3, P = 0.0005) were associated with PRES. Central nervous system (CNS) involvement (odds ratios [OR] = 2.8; 95% CI, 1.2-6.5, P = 0.015) was associated with early PRES and high-risk block treatment (HR = 2.63; 95% CI, 1.1-6.4, P = 0.033) with late PRES. At follow-up of the PRES patients, seven patients had epilepsy and seven had neurocognitive difficulties.Conclusion: PRES is a neurotoxicity in the treatment of childhood ALL with both acute and long-term morbidity. Older age, T-cell leukemia, CNS involvement and high-risk block treatment are risk factors for PRES. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
653 | a ALL | |
653 | a neuroimaging | |
653 | a PRES | |
653 | a seizures | |
700 | 1 | a Eriksson, Mats A.u Karolinska Institutet4 aut |
700 | 1 | a Heyman, Matsu Karolinska Institutet4 aut |
700 | 1 | a Wang, Chenu Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden;Karolinska Univ Hosp, Stockholm, Sweden4 aut |
700 | 1 | a Niinimäki, Riittau Oulu Univ Hosp, Dept Children & Adolescents, Oulu, Finland;Univ Oulu, PEDEGO Res Unit, Oulu, Finland4 aut |
700 | 1 | a Mikkel, Sirjeu Univ Tartu, Dept Hematol & Oncol, Tartu, Estonia4 aut |
700 | 1 | a Vaitkeviciene, Goda E.u Vilnius Univ Hosp Santaros Klin, Childrens Hosp, Vilnius, Lithuania;Vilnius Univ, Vilnius, Lithuania4 aut |
700 | 1 | a Johannsdottir, Inga Mariau Oslo Univ Hosp, Dept Pediat Hematol Oncol, Oslo, Norway4 aut |
700 | 1 | a Myrberg, Ida Hedu Karolinska Institutet4 aut |
700 | 1 | a Jonsson, Olafur Gisliu Univ Iceland, Dept Pediat, Reykjavik, Iceland4 aut |
700 | 1 | a Als-Nielsen, Bodilu Rigshosp, Univ Hosp, Dept Pediat & Adolescent Med, Copenhagen, Denmark;Univ Copenhagen, Fac Med, Inst Clin Med, Copenhagen, Denmark4 aut |
700 | 1 | a Schmiegelow, Kjeldu Rigshosp, Univ Hosp, Dept Pediat & Adolescent Med, Copenhagen, Denmark;Univ Copenhagen, Fac Med, Inst Clin Med, Copenhagen, Denmark4 aut |
700 | 1 | a Banerjee, Joannau Univ Helsinki, Childrens Hosp, Dept Pediat Hematol Oncol & Stem Cell Transplanta, Helsinki, Finland;Helsinki Univ Hosp, Helsinki, Finland4 aut |
700 | 1 | a Harila-Saari, Arja H.u Uppsala universitet,Barnneurologi/Barnonkologi4 aut0 (Swepub:uu)arjha456 |
700 | 1 | a Ranta, Susannau Karolinska Institutet4 aut |
710 | 2 | a Karolinska Institutetb Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden;Karolinska Univ Hosp, Stockholm, Sweden4 org |
773 | 0 | t Pediatric Blood & Cancerd : WILEYg 66:5q 66:5x 1545-5009x 1545-5017 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-381105 |
856 | 4 8 | u https://doi.org/10.1002/pbc.27594 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:140589202 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy